Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- DARPP32 phosphothr-34 thr-34 PPP1R1B PPR1B phosphoprotein FLJ20940 FLJ-20940
- Product Overview:
Dopamine and cAMP-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32) is a member of the protein phosphatase inhibitor 1 family and is encoded by the PPP1R1B gene in humans.{53496} It is primarily expressed in medium spiny neurons of dopamine-innervated brain regions and is localized to the cytoplasm.{53497} DARPP-32 contains multiple phosphorylation sites that allow it to function as a central regulator and integrator of signaling cascades induced by a variety of neurotransmitters, neuropeptides, and psychostimulatory agents. It also contains a protein phosphatase 1 (PP1) binding domain.{53498} DARPP-32, when phosphorylated at the threonine in position 34 (phospho-Thr34) by PKA, is a PP1 inhibitor.{53496} Phosphorylation of DARPP-32 at Thr34 is induced by GABA in rat striatal and substantia nigra slices.{53499} Mice expressing a point mutation of Thr34 (T34A) in DARPP-32, which abolishes its phosphorylation, have reduced cocaine-induced conditioned place preference compared to wild-type mice.{53500} DARPP-32 (phospho-Thr34) levels are decreased in postmortem-derived prefrontal cortex from individuals with schizophrenia.{53501} Cayman’s DARPP-32 (Phospho-Thr34) Polyclonal Antibody can be used for Western blot (WB) applications. The antibody recognizes DARPP-32 (phospho-Thr34) at approximately 32 kDa from mouse and rat samples.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.